PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsCRISPR gene therapy for sickle cell disease approved by the FDA

BioNews

CRISPR gene therapy for sickle cell disease approved by the FDA

Published 9 April 2021 posted in News and appears in BioNews 1090

Author

Dr Molly Godfrey

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

A clinical trial for a new gene therapy approach to treat sickle cell disease has been approved to proceed by the US Food and Drug Administration...

A clinical trial for a new gene therapy approach to treat sickle cell disease has been approved to proceed by the US Food and Drug Administration. 

Patients with sickle cell disease have a mutation in the beta-haemoglobin gene, causing them to produce misshapen red blood cells that can block blood vessels leading to severe pain, anaemia and potentially life-threatening complications, such as organ damage and strokes. Currently, the only cure is a stem cell transplant from a healthy donor, but in the newly-approved trial, scientists from the University of California will use CRISPR/Cas9 genome editing to replace the faulty gene with a functional version. 

'Gene therapy and genome editing allow each patient to serve as their own stem cell donor,' said Professor Donald Kohn, from the Broad Stem Cell Research Centre at the University of California Los Angeles, one of the clinical trial leaders. 'In theory, these approaches should be much safer than a transplant from another person and could become universally available because they eliminate the need to find the needle in a haystack that is a matched stem cell donor.'

In the trial, blood stem cells will be harvested from the patients and grown in the lab. CRISPR/Cas9 will be used to 'cut and replace' a sequence of DNA containing the mutation with a healthy copy. The edited cells will then be returned to the patient's body in the same way they would be if the patient was receiving donor stem cells.

'The goal of this form of genome editing therapy is to correct the mutation in enough stem cells so the resulting blood in circulation has corrected red blood cells,' said Dr Mark Walters, from the University of California San Francisco Benioff Children's Hospital, another of the clinical trial leaders. 

The study will take place over four years, and include six adults and three adolescents with severe sickle cell disease, testing both safety and efficacy. 

The treatment does have risks: the patients will need to have high dose chemotherapy, to kill all remaining blood stem cells before the modified stem cells are put back. This is also necessary before receiving donor stem cells and can cause severe side effects as the patient's immune system is temporarily disabled.

A similar trial, using CRISPR/Cas9 to activate bone marrow stem cells to produce an alternative version of haemoglobin, rather than correcting the faulty version, has recently shown promising results in a patient with sickle cell disease (see BioNews 1052).

Sources and References

  • 30/03/2021
    University of California, Berkeley
    FDA approves first test of CRISPR to correct genetic defect causing sickle cell disease
  • 30/03/2021
    University of California San Francisco
    UC Consortium launches first clinical trial using CRISPR to correct gene defect that causes sickle cell disease
  • 03/03/2021
    Innovative Genomics Institute
    CRISPR clinical trials: a 2021 update
  • 01/04/2021
    The Daily Californian
    FDA approves CRISPR gene therapy trials for sickle cell disease
  • 31/03/2021
    The Mercury News
    UC launches gene therapy trial to transform the treatment of sickle cell disease

Related Articles

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
29 April 2022 • 2 minutes read

Young men with sickle cell disease unaware of related fertility issues

by Dr Malena Daich Varela

Adolescent boys and young men with sickle cell disease are not sufficiently aware of the impact of the disease on their fertility...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
4 March 2022 • 2 minutes read

CRISPR genome editing treatment still effective after one year

by James Moore

The first team to use CRISPR to edit a disease-causing gene in humans has found the effects are persistent up to a year later...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Reviews
3 September 2021 • 4 minutes read

Podcast Review: CRISPR Stops Rare Genetic Disease in New Human Trial

by Beatrice Costa

Genome editing is a group of approaches that enable scientists to add, remove or alter selected DNA sequences at particular locations in the genome...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
13 August 2021 • 2 minutes read

More positive results from CRISPR trial for sickle cell and thalassaemia

by Dr Charlotte Douglas

A genome-editing-based gene therapy for blood diseases sickle cell disease and beta-thalassaemia continues to be effective more than two years after treatment...

PET BioNews
News
23 July 2021 • 2 minutes read

Women with sickle cell not given adequate information about reproductive health

by Jen Willows and 1 others

A knowledge gap may mean that women and girls living with sickle cell disease are not getting the best reproductive healthcare...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
19 June 2020 • 2 minutes read

CRISPR trial shows promising results for sickle cell and thalassaemia

by Javier Bautista

CRISPR genome editing has been successfully used to treat three patients with blood disorders in a clinical trial...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
10 January 2020 • 3 minutes read

The potential use of CRISPR to treat disease is gaining momentum

by Bernie Owusu-Yaw

Promising results from clinical trials give hope for using CRISPR genome editing to treat various heritable diseases and cancer in humans...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
10 March 2017 • 2 minutes read

Sickle cell reversed with gene therapy in teenager

by Ayala Ochert

A teenage boy in France appears to have been cured of sickle cell disease using a gene therapy. He has been free of all signs of the disease for 15 months...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
12 September 2016 • 2 minutes read

Study brings sickle-cell gene therapy one step closer

by Dr Nicoletta Charolidi

A genetically engineered virus that triggers the production of an alternative form of haemoglobin has reversed the symptoms of sickle cell disease in mice...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Y-chromosome-linked infertility discovered

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Common virus may be cause of recent hepatitis cases in children

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

1 August 2022 • 2 minutes read

CRISPR genome editing treatments may raise cancer risk

1 August 2022 • 2 minutes read

Differences in IVF-conceived children's size disappear by adolescence

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856